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Abstract 
 
As mitochondrial dysfunction is evident in neurodegenerative disorders that are 
accompanied by pain, we generated inducible mutant mice with disruption of 
mitochondrial respiratory chain complex IV, by COX10 deletion limited to sensory 
afferent neurons through the use of an Advillin Cre-reporter. COX10 deletion results 
in a selective energy-deficiency phenotype with minimal production of reactive 
oxygen species. Mutant mice showed reduced activity of mitochondrial respiratory 
chain complex IV in many sensory neurons, increased ADP:ATP ratios in dorsal root 
ganglia and dorsal spinal cord synaptoneurosomes, as well as impaired 
mitochondrial membrane potential, in these synaptoneurosome preparations. These 
changes were accompanied by marked pain hypersensitivity in mechanical and 
thermal (hot and cold) tests without altered motor function. To address the underlying 
basis, we measured Ca2+ fluorescence responses of dorsal spinal cord 
synaptoneurosomes to activation of the GluK1 (kainate) receptor, which we showed 
to be widely expressed in small but not large nociceptive afferents, and is minimally 
expressed elsewhere in the spinal cord. Synaptoneurosomes from mutant mice 
showed greatly increased responses to GluK1 agonist. To explore whether altered 
nucleotide levels may play a part in this hypersensitivity, we pharmacologically 
interrogated potential roles of AMP-kinase and ADP-sensitive purinergic receptors. 
The ADP-sensitive P2Y1 receptor was clearly implicated. Its expression in small 
nociceptive afferents was increased in mutants, whose in vivo pain hypersensitivity, 
in mechanical, thermal and cold tests, was reversed by a selective P2Y1 antagonist. 
Energy depletion and ADP elevation in sensory afferents, due to mitochondrial 
respiratory chain complex IV deficiency, appear sufficient to induce pain 





Mitochondrial dysfunction is associated with a wide range of neuropathic pain states, 
[1] including peripheral neuropathies induced by anti-cancer [2,3] and anti-retroviral 
therapy [4], diabetic hyperglycaemia [5,6] and traumatic nerve injury [7]. 
Neurodegenerative disorders displaying pain phenotypes, such as Charcot-Marie-
Tooth disease and multiple sclerosis [8-11] also display mitochondrial defects [12-
15]. 
A number of processes ensuing from mitochondrial dysfunction have been 
implicated in leading to pain hypersensitivity. These include neurotoxicity from the 
production of reactive oxygen species (ROS), disturbances in mitochondrial 
fission/fusion dynamics and frank depletion of ATP levels [16-19,2,20-24]. The 
reduced efficiency of Na+/K+ ATPase resulting from ATP depletion has been 
suggested to cause increased excitability and neuropathy-associated ectopic firing in 
primary sensory afferents [25]. In animal models of chemotherapy-induced peripheral 
neuropathy (CIPN), where mitochondrial dysfunction is associated with hyperalgesia, 
beneficial effects of antioxidants and a selective inhibitor of mitochondrial fission 
have been reported [19,26-30]. In peripheral neuropathy patients, while currently 
available antioxidants display partial reversal of hypersensitivity, this is relatively 
modest in magnitude [19], suggesting that mechanisms additional to ROS toxicity 
play a significant part in driving pain hypersensitivity. 
Genetically modified mouse models of disrupted mitochondrial function in 
sensory neurons could potentially help to elucidate downstream pathogenic 
mechanisms including those responsible for causing pain hypersensitivity [31]. 
Interestingly, inducible disruption of mitochondrial respiratory chain complex IV 
function in the nervous system (targeting the COX10 gene) produced a delayed 
onset of neuropathology associated with energy deficit in the absence of ROS 
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production [32]. Using a similar approach here, but regionally targeting the mutation 
to primary sensory neurons by crossing to an Advillin gene Cre-reporter [33], we 
have been able to elucidate the functional outcome of selective mitochondrial energy 
depletion in sensory afferents. We report robust pain hypersensitivity, implicate 
activation of the ADP-sensitive P2Y1 receptor in its generation, and demonstrate 







All animal breeding, maintenance and experimental procedures were carried out in 
accordance with the UK Animals (Scientific Procedures) Act 1986 and were 
approved by the University of Edinburgh’s Local Ethical Review Board. Animals were 
housed under a 12h light-dark cycle and given access to food and water ad libitum.  
C57/Bl6J double transgenic mice were produced using an inducible Cre-LoxP 
recombination system. Mutants expressed floxed COX10fl/fl, encoding a farnesyl 
transferase, essential for the function of mitochondrial respiratory chain complex IV 
[34] and tamoxifen-inducible Cre-recombinase [35] under the promoter for Advillin 
(Adv), a peripheral sensory neuron-specific marker expressed in over 90% of dorsal 
root ganglion (DRG) cells [33]. This produced DRG-specific mitochondrial mutants 
(COX10fl/fl Adv-CreERT2+/-), which were compared with COX10-floxed, but Cre-
lacking controls (COX10fl/fl Adv-CreERT2-/-) that had been similarly treated with 
tamoxifen. COX10 deletion in the double transgenics was achieved by intraperitoneal 
injection of tamoxifen (Sigma). Tamoxifen was dissolved in 10:1 sunflower oil/clinical 
grade ethanol at 10 mg/ml and injected intraperitoneally at a dose of 0.18mg/g body 
weight per day from P28 for 5 consecutive days. Experiments were carried out 6.5 
weeks later using mice of either sex. Tissue specific gene deletion was previously 
confirmed using Southern blots [32] and in situ hybridisation [36]. Disruption of 
complex IV by COX10 deletion using a constitutive Cre promoter has been reported 
to represent a specific energy failure phenotype with minimal ROS production for up 
to 4 months [32].   
 
Sensory/motor testing in vivo 
 
Six and a half weeks following induction with tamoxifen, mutant and control mice 
were weighed and general motor function/co-ordination was tested by Rotarod 
(UgoBasile, Varese), by measuring the (duration of maintained running at 24 rpm for 
4 cycles of 2 min with 5 min intervals of rest in between the running cycles. In 
addition, hindlimb muscle strength was assessed by Grip Strength Meter (BioGS3, 
BioSeb) as maximum maintained force in g. Mechanical and thermal nociceptive 
sensitivity were also assessed using standard behavioural tests, during which, the 
investigator was blinded to genotype. Mechanical nociception was assessed as paw 
withdrawal threshold (in g) from force-calibrated von Frey nylon filaments (Stoetling, 
Illinois). Nociceptive heat sensitivity was measured as paw withdrawal latency (in 
sec) using Hargreaves’ infrared apparatus (Linton Instrumentation), set to a 
maximum temperature of 52 oC and a cut-off time of 20 sec. Testing was always 
separated by at least 5 min to avoid sensitisation of responses. Nociceptive cold 
sensitivity was measured as cold-plate standing duration (in sec) using a simple 
thermal choice chamber with a metal plate kept at the temperature of iced water 
(~4oC) versus a polystyrene platform at room temperature. In experiments assessing 
drug effects, time-course data were obtained for the von Frey and Hargreaves’ reflex 
paw withdrawal tests, but in the cold avoidance test, readings were taken just before 
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and 30 min after drug administration to avoid any effect of learning due to repeated 
testing.  
Assays of mitochondrial function  
To quantify any changes in ATP and ADP levels in sensory afferent neuronal cell 
bodies of mutant mice compared to controls, DRG were rapidly removed and snap 
frozen on dry ice before weighing and homogenisation in ice cold 1 M perchloric acid. 
After micro-titration to pH 7.0 with 4M KOH, samples were centrifuged to obtain 
neutralised, de-proteinised extracts. Aliquots were added to 96-well assay plates and 
assayed independently for ATP and ADP using fluorometric enzyme-linked assay 
kits (Abcam, ab83355 and ab83359), according to the manufacturer’s protocols. 
Internal standard curves allowed quantification and after volume correction, values 
were expressed as nmol/mg DRG wet weight. To assess any alterations in relative 
ADP:ATP levels in dorsal spinal cord (where sensory afferent terminals are located), 
dorsal, as well as ventral, spinal cord synaptoneurosomes (see below) were assayed 
using an enzyme-linked bioluminescence kit (Abcam, ab65313) [18], which displays 
very high sensitivity measurement of the nucleotides, but in terms of relative, rather 
than absolute concentrations.  
Mitochondrial respiratory chain functionality was assessed by sequential 
histochemical evaluation of cytochrome c oxidase (COX; complex IV) and succinate 
dehydrogenase (SDH; complex II) activity [14]. In brief, COX media (100 µM 
cytochrome c, 4 mM diaminobenzidine tetrahydrochloride and 20 µg ml-1 catalase in 
0.1 M phosphate buffer pH 7.0) was applied to snap-frozen cryosections of whole 
spinal cord with DRG for 40 min, washed in PBS before SDH medium (130 mM 
sodium succinate, 200 mM phenazine methosulphate, 1 mM sodium azide and 1.5 
mM nitroblue tetrazolium in 0.1 M phosphate buffer pH 7.0) was applied for a further 
20 min at 37oC.  
To assess whether AdvCOX10 mutants showed elevated levels of ROS 
compared to controls, dorsal and ventral spinal cord synaptoneurosomes (see below) 
were loaded with the broad-spectrum fluorometric ROS reporter, 5-(and 6)-
chloromethyl-2’,7’-dichlorohydrofluorescein diacetate (CM-H2DCFDA; Molecular 
Probes), 2 µM, 30 min, 37oC [37]. Fluorescence was read at excitation 495 nm, 
emission 525 nm, and compared in each case to a maximal positive control provided 
by the ROS donor tert-butyl hydroperoxide (t-BuOOH; Sigma), 5 mM, 30 min, 37oC 
[21,17].  
Assessment of relative mitochondrial membrane potential was carried out 
using the ratiometric fluorescent probe JC-1 (Molecular Probes, Invitrogen). JC-1 is a 
cationic carbocyanine that accumulates in mitochondria according to their membrane 
potential and at higher concentrations transitions from the green-fluorescing 
monomer to a red-fluorescing aggregate [38,39]. Synaptoneurosomes were prepared 
from dorsal or ventral spinal cord of mutant or control mice (see below), aliquoted 
into 48-well plates, and pre-incubated at 37oC before addition of 1.5 µM JC-1 for 30 
min before fluorescent measurement at excitation, 488nm; emission 525 and 595 
nm. In some control experiments, samples were incubated with the ETC uncoupler, 
carbonyl cyanide-p-trifluomethoxyphenylhydrazone, (FCCP; 1 µM) for 45 min to 
depolarise the mitochondrial membrane potential and in all cases this resulted in 
around 75% reduction in the red:green emission ratio.  
Synaptoneurosome preparation and measurement of Ca2+ fluorescence 
responses   
A key measure of the significance of biochemical changes in nociceptive primary 
sensory neurons is the impact on neurotransmission at synapses between their 
central terminals and postsynaptic neurons in spinal dorsal horn. To investigate this 
in AdvCOX10 mutant mice, compared to controls, we prepared synaptoneurosomes 
from dorsal spinal cord. Synaptoneurosomes are re-sealed pre-synaptic and closely 
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apposed post-synaptic elements, freshly prepared from CNS tissue [40,41]. 
Protocols that optimise metabolic and ionic integrity in synaptoneurosomes have 
been recently developed in our laboratory so dynamic Ca2+ fluorescence responses 
to receptor stimuli can be measured [42,43]. Thus, we were able to assay 
neurotransmission at the first central synapses of nociceptive afferents, using as a 
stimulus, an excitatory receptor abundantly expressed on presynaptic terminals of 
nociceptive afferents (the GluK1, kainate receptor), and as a read-out, Ca2+ 
fluorescence, which reflects mainly the signal from the postsynaptic compartment 
[42,43].  
Lumbar spinal cord segments (L4-6) were rapidly removed from animals after 
cull and immediately homogenised in ice-cold, highly-oxygenated medium using a 
hand-held teflon-glass homogeniser. The medium was divalent ion-free Krebs-
Henseleit buffer, additionally containing HEPES (10 mM, pH 7.4), sodium pyruvate 
(0.5 mM), glutathione (5 µM), creatine phosphate (2 mM), magnesium chloride (5 
mM), sodium kynurenate (0.3 mM) and Type III protease inhibitor cocktail 
(Calbiochem, 1:1000). The homogenate was rapidly syringe-filtered through a 30 µm 
nylon mesh filter and then through a 5µm pore mixed cellulose fibre matrix filter 
(Millipore) before centrifugation at 1,500 g for 15 min at 4 ºC. The pellet was 
resuspended in ice-cold highly-oxygenated medium as above but lacking magnesium 
ions and kynurenate. Electron microscopic analysis of this subcellular fraction 
revealed the abundant presence of small dual-compartment re-sealed profiles 
consistent with the previously described characteristics of synaptoneurosomes [40]. 
Aliquots of synaptoneurosome suspension (150 µl) were dispensed into 48-well 
plates and Calcium-5 (a sensitive, no-wash Ca2+ fluorophore, formulated with an 
extracellular fluorescence quenching agent; Molecular Devices), was added in 50 µl 
resuspension buffer containing 8 mM CaCl2, before incubation for 45 min at 37 
oC 
under 95% O2 / 5% CO2. For the current series of experiments, Concanavalin A 
(ConA; 300 µg/ml) was added 10 min prior to assay, to minimise GluK1 receptor 
desensitisation [44-46]. Plates were transfered to the plate reader (Varioskan Flash, 
ThermoScientific; thermostatted at 28oC). Pharmacological agents were then added 
(modulatory antagonists, then agonists, before GluK1 activator) immediately before 
recording at 12 x 30 sec intervals or 6 x 1 min intervals. Intracellular Ca2+ 
fluorescence was read at excitation 488 nm, emission 518 nm. Ionomycin (10 µM) 
and basal measurements were included in every plate to calibrate the dynamic range 
of the assay. The following pharmacological agents were used: the selective GluK1 
agonist, 5-iodowillardiine (5-IW; Tocris); the selective GluK1 antagonist, ACET 
(Tocris); the selective GluA agonist, R,S-AMPA (Abcam); the inhibitor of synaptic 
vesicle exocytosis, tetanus toxin (Sigma-Aldrich); the inhibitors of glutamate receptor 
desensitisation, Concanavalin A (ConA, Sigma-Aldrich) and cyclothiazide (Tocris); 
the selective P2Y1 agonist, MRS 2365 (Tocris); the selective P2Y1, P2Y12 and P2Y13 
antagonists, MRS 2500, AZD 1283 and MRS 2211, respectively (Tocris); the 
selective AMP-Kinase (AMPK) activators, AICAR and A697662 (Abcam); the AMPK 
inhibitor, dorsomorphin (Abcam); and the Ca2+ ionophore, ionomycin (Abcam).  The 
concentrations used for each agent were selected on the basis of publications 
showing substantial efficacy in cellular assays or at generally 10-20 fold the reported 
in vitro EC50/IC50 concentrations.  
Immunofluorescence histochemistry 
DRGs from spinal segments L4-6 were dissected, rapidly embedded in OCT cryo-
sectioning medium (Thermo Scientific) and frozen on dry ice. 20 µm sections were 
cut by cryostat and mounted onto poly-L-lysine coated slides (Thermo Scientific). 
Sections were washed in Tris-Buffered Saline (TBS) pH 7.60 and then incubated for 
1 h at room temperature in blocking buffer (10% normal donkey serum, 4% fish skin 
gelatin, 0.2% Triton X-100 in TBS) prior to overnight incubation at 4°C with a 
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combination of primary antibodies in buffer (4% normal donkey serum, 4% fish skin 
gelatin and 0.2% Triton X-100 in TBS). The primary antibodies used were: rabbit 
polyclonal anti-GluK1 (Alomone, AGC-008, 1:500), chicken polyclonal anti-peripherin 
(Abcam, ab39374, 1:7500), guinea pig polyclonal anti-TRPV1 (Abcam, ab10295, 
1:3000), rabbit polyclonal anti-P2Y1 (Alomone, APR-021, 1:650).  Sections were 
washed in TBS and incubated for 1 h at room temperature with a combination of 
secondary antibodies or Alexa Fluor-488 conjugated isolectin IB4 (Invitrogen; I21411; 
1:3000) in buffer (4% normal donkey serum, 4% fish skin gelatin in TBS). Extensively 
cross-adsorbed secondary antibodies were: donkey anti-guinea pig CF-405 (Sigma-
Aldrich; SAB4600231; 1:600) and donkey anti-rabbit Alexa Fluor-568 (Life 
Technologies; A10042; 1:600) and donkey anti-chicken CF-488 (Sigma-Aldrich; 
SAB4600031; 1:600). Sections were washed three further times in TBS and then 
mounted in ProLong® Gold Antifade (Life Technologies) before visualisation through 
a x20 objective using a Nikon A1R confocal microscope. Standard primary antibody 
omission or blocking peptide controls, wherever possible, confirmed that non-specific 
staining was minimal.	  	  
 
Western blotting  
Samples were solubilised in x2 Laemmli buffer: 50 mM Tris, pH 7.4 containing 5% 
mercaptoethanol and 2% sodium dodecyl sulphate, SDS, Sigma). The samples were 
thoroughly mixed and heated at 80ºC for 10 min and then either used immediately or 
stored at -20 ºC. Proteins were separated by SDS-PAGE (SDS-polyacrylamide gel 
electrophoresis) using the NuPage XCell SureLockTM Minicell gel electrophoresis 
system (Invitrogen). Samples (5 µl) were mixed with 1 µl loading solution (0.04% w/v 
Bromophenol Blue in glycerol) and added to the wells of 4–12% Bis-Tris NuPage 
gels. Pre-stained standard molecular weight proteins (Spectra Multicolor Broad 
Range Protein Ladder; Thermo-Pierce) were run alongside. Samples were 
electrophoresed using NuPage MOPS running buffer (Invitrogen) under a 200 V 
potential difference. Proteins were transferred to polyvinylidene difluoride membrane 
Immobilon-PSQ, Millipore) at 30 V in transfer buffer (5% NuPage transfer buffer, 10% 
methanol) for 90 min. Membranes were incubated for 60 min in blocking buffer (5% 
bovine serum albumin (BSA) in 0.1 M Tris-buffered saline (TBS), pH 7.60, with 0.1% 
Tween-20) to reduce non-specific binding. Membranes were then washed and 
incubated overnight at 4ºC in 2% BSA in 0.1 M TBS with 0.1% Tween-20, containing 
rabbit monoclonal anti-phospho-AMPKα (Thr172) (Cell Signaling Technology, #2535, 
1:500). Membranes were washed and incubated for 50 min at room temperature with 
peroxidase-conjugated goat anti-rabbit secondary antibody (Chemicon, 1:40,000). 
Bands were detected by peroxidase-linked enhanced chemiluminescence and X-ray 
film (ECL reagent; Immobilon, Millipore, and Hyperfilm; GE Healthcare). After 
washing, membranes were re-probed with mouse monoclonal anti-GAPDH (Millipore, 
#MAB 374, 1:5,000) for 30 min at room temperature. Membranes were washed and 
incubated with peroxidase-conjugated goat anti-mouse secondary antibody 
(Chemicon, 1:40,000) for 30 min at room temperature. Bands were detected by ECL 
reagent and X-ray film, as before. Films were scanned and band intensities were 
quantified by densitometry using Image J. 
	  
Non-linear curve-fitting and statistical analysis 
All data analysis was carried out using GraphPad Prism. Non-linear curve-fitting used 
a sigmoidal dose-response (variable slope) model. Data in two-group format were 
analysed statistically by Student’s t-test.  Comparisons between more than two 
groups were made by One-Way ANOVA with Tukey’s or Dunnett’s test, or by Two-
Way ANOVA with Bonferroni’s test.  
 




Assessments of mitochondrial function confirm an energy failure phenotype in 
sensory afferents of AdvCOX10 mutants 
 
We used a range of distinct approaches to establish that disruption of mitochondrial 
energy production was occurring in neuronal sensory pathways of the AdvCOX10 
mutant mice at 6.5 weeks after the start of tamoxifen induction. In flash-frozen DRG, 
we used micro-scaled, enzyme-linked fluorometric assays to quantify ATP and ADP 
content. Figure 1A shows that ATP concentrations were significantly reduced and 
ADP concentrations were significantly increased in AdvCOX10 mutant compared to 
control mice. Correspondingly, the ADP:ATP ratio was more than two-fold greater in 
AdvCOX10 mutants than in controls.  
To measure ADP:ATP ratios in the region of primary afferent neuron 
termination, in spinal dorsal horn, we used an enzyme-linked, bioluminescent 
ratiometric assay in synaptoneurosomes from dorsal and ventral spinal cord of 
AdvCOX10 mutants and control mice (Figure 1C). ADP:ATP ratios were significantly 
increased in dorsal (but not ventral) spinal cord synaptoneurosomes from AdvCOX10 
mutant mice compared to controls.   
In addition, we used a sequential histochemical staining approach to identify 
DRG cells showing cytochrome c oxidase deficiency (lacking complex IV activity with 
intact complex II). Figure 1B shows that numerous complex IV-deficient DRG cell 
bodies lacking the brown staining, and identified by the greatly increased complex II 
activity, with blue staining were evident in AdvCOX10 mutants, but not in control 
mice. In contrast, spinal cord ventral horn neurons showed no blue staining that 
would have been indicative of complex IV deficiency. 
We further evaluated mitochondrial membrane potential in dorsal/ventral 
spinal cord synaptoneurosomes using the ratiometric fluorescent dye, JC-1 (Figure 
1D). In dorsal spinal cord the JC-1 595:525 nm fluorescence ratio (a measure of 
effective mitochondrial membrane potential) was significantly reduced in AdvCOX10 
mutants compared to controls. No such change was apparent in ventral spinal cord 
samples, consistent with the expectation that the Adv promoter would target the 
COX10 deletion to neurons of peripheral origin; that is sensory afferents terminating 
in dorsal rather than ventral spinal cord. In support of the idea that JC-1 was 
effectively reporting mitochondrial membrane potential here, the mitochondrial 
depolarising agent and ATP-synthesis uncoupler, (FCCP, 1 µM, 45 min, 37oC) 
significantly reduced 595:525 fluorescence ratios in all cases (p<0.01, n = 5, t-test). 
The mean percentage inhibition values due to FCCP were 74.3% and 73.5% in 
control dorsal and ventral spinal cord samples, with corresponding values of 74.5% 
and 57.4% in AdvCOX10 mutants.     
To assess whether elevated ROS levels (a possible contributor to 
hypersensitivity) were present in AdvCOX10 mutants compared to controls, we 
prepared synaptoneuromes from dorsal and ventral spinal cords and loaded these 
with the broad-spectrum fluorometric ROS reporter, CM-H2DCFA. In comparison with 
a robust positive control signal from the potent ROS donor, t-BuOOH, we found no 
evidence of elevated ROS levels in AdvCOX10 mutant mice relative to controls 
(Figure 1E). Fluorescence values from the ROS reporter were less than 15% of 
those in the presence of t-BuOOH in all cases, with no significant difference between 
dorsal spinal cord of AdvCOX10 mutants or control mice, and similar results in 
ventral spinal cord.  
All these observations are consistent with the idea that disruption of COX10 
produces predominantly an energy failure phenotype that is not associated with 
excess ROS production [32].     
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AdvCOX10 mutants display marked hypersensitivity in mechanical and thermal             
(hot and cold) pain behaviours 
 
To assess any functional sensory consequences of Adv-directed COX10 deletion we 
used von Frey filament testing of mechanical paw withdrawal threshold (Figure 2A), 
Hargreaves’ apparatus testing of thermal paw withdrawal threshold to noxious heat 
(Figure 2B), and noxious cold plate standing duration (Figure 2C). In each test there 
was greater than 2-fold hypersensitivity in AdvCOX10 mutants compared to controls 
(statistically significant in each case). These findings indicate that disrupted 
mitochondrial energy production in sensory neurons leads to marked pain 
hypersensitivity. Figure 2D shows that the general health (weight gain) and motor 
function in AdvCOX10 mutants were not significantly different compared to controls 
at 6.5 weeks after completing tamoxifen treatment. This confirms the sensory 
modality-specific hypersensitivity in the mutants, while general health and motor 
function showed no discernible deficit.  
 
GluK1 receptor expression in nociceptive afferents  
 
Excitatory GluK1 receptors and their mRNA are reported to be widely expressed in 
small nociceptive afferents and minimally expressed elsewhere in spinal cord 
[47,44,48,45,49,50]. A major role for GluK1 in particular in DRG is emphasized by 
the abrogation of DRG neuron excitatory responses to kainate receptor agonists in 
GluK1-/- mice [51,52]. We therefore investigated whether pharmacologically targeting 
GluK1 would be an appropriate way to monitor responsiveness to a broad spectrum 
of nociceptive afferents. Dual label immunofluorescence evaluation of GluK1 
expression in DRG, confirmed its selective distribution, with more than 90% of 
GluK1-positive cells co-staining for the unmyelinated C-fibre marker, peripherin 
(Figure 3A). Both presumed peptidergic C-fibres, immunoreactive for TRPV1 [53], 
and presumed non-peptidergic C-fibres, labeled with isolectin IB4 [54]  showed 
GluK1-immunoreactivity in around half of the population (Figure 3B). There were no 
significant differences between control and AdvCOX10 mutant mice in the 
percentages of peripherin+, TRPV1+ or IB4+ DRG cells expressing GluK1. 	  
 
Ca2+ fluorescence responses elicited by GluK1 receptor activation in dorsal 
spinal cord synaptoneurosomes 
 
In ex vivo dorsal spinal cord synaptoneurosomes from control mice we showed that 
the selective GluK1 agonist, 5-iodowillardiine (5-IW; [55-57,46]), produced a 
concentration-dependent increase in Ca2+ fluorescence with a mean EC50 value [95% 
confidence interval] of 242 [205/285] nM (Figure 3C). The selective GluK1 antagonist 
ACET [58], at a concentration of 100 nM, produced a rightward shift in the 5-IW 
concentration-response curve with a 5.3-fold increase in mean EC50 value to 1.29 
[0.88/1.87] µM (p<0.0001 by Extra Sum of Squares F-test; Figure 3C). Responses to 
2 µM 5-IW were markedly reduced by 45 min pre-incubation with the inhibitor of 
exocytosis, tetanus toxin [59], reaching a maximum effect of 85.8 ± 4.9% inhibition 
(mean ± SEM, n = 4) at a concentration of 20 nM (p<0.01 by One-Way ANOVA with 
Dunnett’s test), consistent with a largely presynaptic site of action for 5-IW. In 
contrast, responses to activation of GluA receptors, which are widely distributed 
postsynaptically, using 20 µM AMPA (in the presence of 10 µM cyclothiazide to 
attenuate desensitisation; [60,61] were minimally affected (21.7 ± 8.7% inhibition at 
20 nM tetanus toxin; p>0.05). Figure 3D shows not only that Ca2+ fluorescence 
responses to 2 µM 5-IW were significantly greater in dorsal compared to ventral 
spinal cord in both control and AdvCOX10 mutant mice (p<0.05 and p<0.001, by 
One-Way ANOVA with Tukey’s test), but also that dorsal responses were 
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significantly greater in AdvCOX10 mutants compared to those in control mice 
(p<0.05). This is entirely consistent with the idea that mitochondrial deficiency due to 
the AdvCOX10 mutation has brought about hypersensitivity at the first central 
synapses of nociceptors in dorsal spinal cord.  
 
Investigation of potential roles for ADP or AMP in the nociceptive 
hypersensitivity seen in AdvCOX10 mutants 
 
As the disruption of mitochondrial respiratory chain complex IV by mutations 
including COX10 is reported to produce predominantly an energy failure phenotype 
[32], we postulated that lower energy forms of adenosine phosphate (ADP or AMP, 
rather than ATP) might play a role in the pain hypersensitivity phenotype. Figure 1 
shows explicitly that the ADP:ATP concentration ratio was increased in AdvCOX10 
mutant DRG and dorsal spinal cord, so we tested whether this might represent an 
active signal that contributes to the development of hypersensitivity.  
Various purinergic receptors are expressed in sensory afferents including 
several (P2Y1, P2Y12 and P2Y13), that are selectively activated by ADP [62,63], so 
could potentially respond to the increased ADP:ATP ratio seen in DRG of AdvCOX10 
mutants. Of these candidates, P2Y1 signals primarily through Gq/11, Ca
2+ and PKC, 
so is anticipated to cause increased excitability, whereas P2Y12 and P2Y13 are 
primarily Gi linked, so are likely to produce broadly inhibitory outcomes [62]. Although 
the literature contains some conflicting reports, the consensus view is that P2Y1 is 
mainly expressed in small DRG cells, negative for the marker of larger myelinated 
neurons, NF-200, with both IB4-positive (non-peptidergic) and CGRP-
positive/capsaicin-responsive (peptidergic) C-nociceptors being represented [64-67]. 
Figure 4 compares the effects of selective P2Y1, P2Y12 and P2Y13 agents [68,69] on 
the 5-IW-induced Ca2+ fluorescence responses of dorsal spinal cord 
synaptoneurosomes from control and AdvCOX10 mutant mice. The increase in 5-IW 
responses seen in mutants compared to controls was significantly reversed by 
blocking P2Y1, but not P2Y12 or P2Y13 (using MRS 2500, AZD 1283 and MRS 2211, 
respectively). Addition of a P2Y1 agonist (MRS 2365) increased 5-IW-induced Ca
2+ 
fluorescence responses in controls, but not to beyond a level that was apparent in 
AdvCOX10 mutants. These results clearly implicate P2Y1 (but not P2Y12 or P2Y13) in 
the hypersensitivity of 5-IW responses seen in AdvCOX10 mutants.	  
Considering that relative levels of AMP might also be increased in the 
AdvCOX10 mutant energy failure phenotype, we investigated any potential role of 
AMP-activated protein kinase (AMPK) in the nociceptive hypersensitivity observed. 
Activation of AMPK has however, been reported to exert antinociceptive effects in 
models of ongoing peripheral neuropathic pain due to trauma, chemotherapeutic 
agents or hyperglycaemia, as well as pain due to inflammation, surgical tissue injury 
or metastatic bone cancer [70-76]. Figure 5A shows that Western blots in dorsal 
spinal cord synaptoneurosomes revealed no increase in phospho-AMPKα 
(Thr172):GAPDH ratios in AdvCOX10 mutants compared to control mice. Figure 5B 
further shows that the AMPK activators AICAR and A697662 actually reduced the 5-
IW-induced Ca2+ fluorescence responses of dorsal spinal cord synaptoneurosomes. 
These antinociceptive effects were similar in extent in both control and AdvCOX10 
mutant mice and clearly were not contributing to the hypersensitivity. The AMPK 
inhibitor, dorsomorphin, had no discernible effect. These observations are at odds 
with the idea of AMPK activation contributing to the nociceptive hypersensitivity seen 
in AdvCOX10 mutants.  	  
 
P2Y1 is widely expressed in nociceptive afferents and this is further increased 
in AdvCOX10 mutants compared to controls 
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As P2Y1 activation had been specifically implicated in the hypersensitivity at first 
central synapses of nociceptive inputs seen in AdvCOX10 mutants, we investigated 
its expression in DRG of both control and AdvCOX10 mutant mice. Figure 6 shows 
that a substantial proportion of peripherin-immunoreactive small nociceptive afferents 
were also positive for P2Y1 and that this proportion was significantly increased in 
AdvCOX10 mutants compared to control mice. The increase was apparent in both 
TRPV1-positive (largely peptidergic) and IB4-positive (non-peptidergic) 
subpopulations of nociceptive afferents. Clearly, not only the increased relative 
concentration of ADP compared to ATP, but also the increased expression of P2Y1 in 
small afferent neurons, is likely to contribute to the nociceptive hypersensitivity in 
AdvCOX10 mutants.   
 
P2Y1 antagonist treatment reverses the pain-associated hypersensitivity of 
AdvCOX10 mutants in vivo and in ex vivo synaptoneurosomes 
 
To assess whether P2Y1 activation plays a critical role in the pain hypersensitivity in 
AdvCOX10 mutants, we treated animals in vivo with the highly selective P2Y1 
antagonist, MRS 2500 (intraperitoneal). Figure 7A shows that reflex Paw Withdrawal 
Thresholds to von Frey filament stimulation were much lower (ie hypersensitive) in 
AdvCOX10 mutants compared to control mice and that this hypersensitivity was 
clearly reversed by MRS 2500 over 15-60 min following administration. MRS 2500 
had no discernible effect in controls. Similar results were observed in the 
Hargreaves’ thermal test (Figure 7B), where MRS 2500 caused significant reversal of 
hypersensitivity in the AdvCOX10 mutants from 15-45 min following administration. 
Increased noxious cold avoidance behaviour in the AdvCOX10 mutants was also 
significantly reversed 30 min after MRS 2500 administration (Figure 7C). 
Assessments were not made at multiple time points in this test, in order to avoid 
learning-associated behavioural adaptation. Figure 7D shows 5-IW-induced Ca2+ 
fluorescence responses of dorsal spinal cord synaptoneurosomes taken from 
animals that had been treated in vivo with MRS 2500, 45 min prior to tissue collection 
(or untreated). The clear increase in 5-IW responses in untreated AdvCOX10 
mutants compared to untreated control mice was significantly attenuated (by around 
50%) in animals treated with MRS 2500. Thus, the hypersensitivity of mutants (both 
in terms of reflex pain behaviour in vivo, and exaggerated responsiveness of ex vivo 





Deficits in mitochondrial function have been reported in a variety of models of 
neuropathic pain. The current results, studying the targeted mutation of a key 
component of the mitochondrial respiratory chain complex IV underline that 
mitochondrial deficits have a causal role in bringing about pain hypersensitivity and 
identify aspects of the mechanism(s) responsible. In models of neuropathic pain 
hypersensitivity due to the administration of chemotherapeutic agents (platinum 
compounds, paclitaxel or bortezomib), deficits in ATP production have been widely 
described [77,30,78]. Similar inhibition of mitochondrial respiratory chain function is 
observed in various models of diabetic neuropathy [79]. Mitochondrial dysfunction 
can induce cellular oxidative stress; generating ROS and leading to cellular oxidative 
damage, including in DRG neurons [80,81]. Both local and systemic treatment with 
antioxidants, or even toxins to inhibit ROS-producing mitochondrial respiratory chain 
complexes, is reported to attenuate CIPN-associated mechanical hyperalgesia 
[27,82,20,83].  
However, the mitochondrial gene deletion model used here (which brings 
about a selective energy-deficient phenotype rather than one of excess ROS 
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generation) indicates that energy deficiency alone is sufficient to cause pain 
hypersensitivity. Direct measurement of ATP/ADP content (in DRG and dorsal spinal 
cord) and histochemical assessment of SDH enzyme activity in DRG, as well as 
monitoring of relative mitochondrial membrane potential using JC-1 indicator in 
dorsal spinal cord all matched the anticipated energy-deficient phenotype, while 
experiments with a broad spectrum ROS-reporter indicated only low levels of ROS 
that were no greater in AdvCOX10 mutants than controls. The Advillin-promoter 
targeting of the deletion to peripheral neurons, caused, as expected, selective 
biochemical deficits in DRG and dorsal, but not ventral, spinal cord. These were 
matched by selective changes in sensory function with no detectable impact on 
motor function or general well-being of the animals. Significant hypersensitivity was 
found in mechanical, heat and cold-induced responses, suggesting a wide impact 
across classes of nociceptive afferents.  
 To investigate the underlying basis in an ex vivo synaptic preparation, readily 
amenable to pharmacological interrogation, we measured Ca2+ fluorescence 
responses of dorsal spinal cord synaptoneurosomes that were elicited by a selective 
GluK1 agonist, 5-IW. The selective GluK1 antagonist, ACET caused an apparently 
parallel right-shift in the 5-IW concentration response curve, in accordance with its 
reported competitive mode of blockade. Responses were also strongly inhibited by 
the presynaptically acting inhibitor of synaptic release, tetanus neurotoxin. This is 
consistent with the reported distribution of GluK1 receptors (selectively in small 
nociceptive afferents and at their corresponding presynaptic terminals in the 
synaptoneurosome preparation). This also matches evidence that neuronal 
mitochondria are particularly enriched at presynaptic terminals, where synaptic 
vesicle trafficking places high demands on ATP synthesis, so presynaptically initiated 
responses may be particularly vulnerable to mitochondrial dysfunction here [84,85]. 
We provided quantitative evidence that GluK1 is expressed in both non-peptidergic 
(IB4+) and likely peptidergic (TRPV1+) nociceptors. This matches previous findings, 
which described GluK1 in both IB4+ and some TRPV1+ cells [48] and suggests that 
GluK1 activation might provide a fair reflection of consensus nociceptive input. 
Correspondingly, both GluK1 antagonists and genetic ablation of GluK1 reduce reflex 
pain behaviour in a number of models of neuropathic or inflammatory pain [86-88]. 
GluK1-mediated Ca2+ fluorescence responses were significantly greater in 
AdvCOX10 mutant dorsal spinal cord than in controls.  
As the ADP:ATP ratio was increased in the DRG and dorsal spinal cord of 
mutants, we investigated the potential contribution of purinergic receptors that might 
respond to this change and are known to be expressed in nociceptive pathways. Of 
the wide range of P2X (ionotropic) and P2Y (metabotropic) purinergic receptors that 
respond to adenine nucleotides, a number have been specifically implicated in pain 
transmission [89,62,90,91]. While many of these are activated by ATP, a few, notably 
P2Y1, P2Y12 and P2Y13 are preferentially activated by ADP, so could be of particular 
relevance to the pain hypersensitivity in AdvCOX10 mutant mice. P2Y12 and P2Y13 
signal predominantly through Gi and are generally thought to lead to inhibitory 
consequences, such as inhibition of Ca2+ channels and facilitation of K+ channels 	  
[62]. In contrast, P2Y1 is coupled to Gq, and will lead to increased Ca
2+ mobilisation 
and activation of protein kinase C, both excitatory processes that in presynaptic 
terminals would be expected to lead to increased transmitter release and central 
sensitisation in pain pathways [62,92]. Further, P2Y1 is not only activated by ADP, 
but inhibited by ATP [63], so will act as an exquisitely sensitive detector of any 
increase in the ADP:ATP ratio. We showed here that P2Y1, but not P2Y12 and P2Y13 
antagonists reversed the increment in GluK1 agonist responses seen in AdvCOX10 
mutant mice. Furthermore, in synaptoneurosomes from control animals, a selective 
P2Y1 agonist replicated the increment in GluK1 agonist responses seen in 
AdvCOX10 mutants. P2Y1 receptors seem likely to be responsible for the 
hypersensitivity seen in AdvCOX10 mutants. 
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As AMP levels could also be increased in an energy-deficient situation due to 
mitochondrial respiratory chain disruption, and thereby activate AMPK, we looked for 
any evidence of AMPK activation in AdvCOX10 mutants compared to controls by 
immunoblotting for phospho-AMPKα (Thr172) in dorsal spinal cord 
synaptoneurosomes and found no support for this idea. Indeed, reports of 
neuropathic pain hypersensitivity due to hyperglycaemia, nerve injury or 
chemotherapeutic toxicity describe reductions, rather than increases in AMPK activity 
[93,73,72]. We further evaluated whether activators or inhibitors of AMPK modified 
the hypersensitivity in GluK1 responses of dorsal spinal cord synaptoneurosomes 
seen in AdvCOX10 mutant mice. The AMPK activators, AICAR and A697662, 
actually reduced GluK1 agonist-induced Ca2+ fluorescence responses in both control 
and AdvCOX10 mutant animals. These observations are consistent with the 
antinociceptive effects of AMPK activators widely reported in neuropathic, 
inflammatory, bone cancer and acute pain models [74,73,71,72,75,76,70]. Our 
findings do not support the idea of AMPK activation contributing to the 
hypersensitivity seen in AdvCOX10 mutant mice.  
 To further assess the likely role of P2Y1 receptors that the pharmacology had 
implied, we measured expression of P2Y1 in afferents of both likely peptidergic and 
non-peptidergic classes. P2Y1 is thought to be expressed in small sensory afferents, 
but not glia [65]. It has been reported that many small nociceptors (of both 
peptidergic and non-peptidergic classes) are immunoreactive for P2Y1 [67], although 
a preferential expression in the non-peptidergic class has been highlighted [66]. We 
found substantial P2Y1 expression in both non-peptidergic (IB4
+) and largely 
peptidergic (TRPV1+) nociceptors. Although TRPV1 and nociceptors have been 
described to largely map to the peptidergic subpopulation [53], other reports indicate 
that TRPV1 may be more widespread [94]. There is evidence that P2Y1 expression in 
nociceptors is up-regulated during neuropathic and inflammatory pain states [95-97], 
potentially enhancing the degree of influence of P2Y1-selective pharmacological 
agents.  
 We then assessed the impact of P2Y1 blockade in vivo on mechanical and 
thermal reflex pain behaviours, noxious cold avoidance behaviour, and the GluK1 
responsiveness in ex vivo tissue from AdvCOX10 mutant and control mice. A highly 
selective P2Y1 antagonist, MRS 2500, at a dose of 2 mg/kg ip, shown to effectively 
block peripheral P2Y1 receptors [98], caused striking analgesia in AdvCOX10 
mutants and correspondingly, MRS 2500 diminished the hypersensitivity in ex vivo 
synaptoneurosomes from the mutant mice. P2Y1 has been suggested to play a role 
in mechanical and thermal sensation [66,99], in the hypersensitivity seen in 
inflammatory, neuropathic and bone-metastasis-induced pain models and in 
regulating new post-inflammation thermal responsiveness [100,101,64,102,103,95]. 
Similar roles for P2Y1 have been described in chronic pain-associated sensitisation 
of visceral and muscle afferent inputs [104,105,97]. These findings in multiple types 
of pain state (including that due to mitochondrial deficiency here) support the idea 
that P2Y1 could represent a widely applicable analgesic target worthy of translational 




Overall, these findings indicate that the energy-deficient phenotype in primary 
sensory afferents found in AdvCOX10 mutants is entirely sufficient to produce pain 
hypersensitivity. Although the tamoxifen-induced deletion was not related here to a 
specific pain model, there is abundant evidence that functional deficiency of the 
mitochondrial respiratory chain complex IV is a common observation in neuropathic 
pain models, so the current findings are likely to be widely applicable in neuropathic 
pain of various origins [106,107]. Blockade of P2Y1, which appears to be selectively 
activated in response to an increased ADP:ATP ratio, could be a useful new strategy 
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for the clinical treatment of neuropathic pain, although any unintended side-effects of 
P2Y1 blockade would need to be considered. Potential applications could include 
neuropathic pain due to nerve damage, toxicity from cancer and retroviral 
therapeutics or diabetic hyperglycaemia, and a range of neurodegenerative 
disorders, each of which has been shown to involve mitochondrial deficits. 
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Figure Legends 
 
Fig. 1 Cellular changes in AdvCOX10 mutant mice. A) ATP/ADP concentrations in 
flash-frozen lumbar DRGs from AdvCOX10 mutant mice, compared to controls, were 
measured using fluorometric enzyme assay kits in 96-well plates. Values are means 
± SEM from 8 control and 7 mutant mice. The left panel shows absolute 
concentrations in nmol/mg DRG wet weight, while the right panel shows ADP:ATP 
ratio. ATP concentrations were significantly reduced in mutant compared to control, 
ADP concentrations were significantly raised, and the ADP:ATP ratio was 
significantly greater (***p<0.001, **p<0.01 and ***p<0.001 respectively; t-tests). B) 
Deficits in functional activity of mitochondrial respiratory chain complex IV, with intact 
SDH activity, were revealed by blue staining using a sequential histochemical assay 
for COX and SDH (COX/SDH). Cells or neuropil with intact complex IV are labeled 
brown, whereas complex IV-deficient cells with blue staining, lack the brown stain. 
Numerous primary sensory neurons in DRG of AdvCOX10 mutants showed 
prominent blue staining, while this was never observed in cells or the dense neuropil 
of spinal cord ventral horn. No blue staining was detected in either DRG or ventral 
horn of control animals. Typical images are shown for control and AdvCOX10 
mutants. Scale bar = 100 µm. C) Relative ADP:ATP concentration ratios were 
measured in dorsal and ventral spinal cord synaptoneurosomes from control and 
AdvCOX10 mutant mice, using a high sensitivity (ratiometric) enzyme-linked 
bioluminescence assay. The relative ADP:ATP ratio was significantly greater in 
dorsal horn of AdvCOX10 mutants compared to control animals (*p<0.05) and 
compared to ventral horn of mutants (†p<0.05); analysis by One-Way ANOVA with 
Tukey’s test, n=7 in each case. D) The relative mitochondrial membrane potential in 
synaptoneurosomes from dorsal and ventral spinal cord (segments L4-6) of 
AdvCOX10 mutants and control mice was measured using the fluorometric probe 
JC-1. JC-1 monomer emits at 525 nm, but accumulates in mitochondria according to 
membrane potential, which results in aggregates that emit at 595 nm (red). The 
red:green fluorescence ratio reflecting mitochondrial membrane potential was 
significantly reduced in dorsal, but not ventral spinal cord of AdvCOX10 mutant mice 
compared to controls (*p<0.05, t-test). Values are means ± SEM, n = 5 in each case. 
E) CM-H2DCFA fluorescence readings of dorsal and ventral spinal cord 
synaptoneurosomes from control and AdvCOX10 mutant mice, reflecting relative 
levels of ROS. Values were normalized to those in the presence of a positive control, 
the ROS donor, t-BuOOH (5 mM, 30 min). In all cases, values were less than 15% of 
the positive control, with no significant differences between dorsal and ventral cord of 
either mutant or control animals, by One-Way ANOVA with Tukey’s test, n=4 in each 
case.      
 
Fig. 2 Changes in nociceptive behavioural responses and general physiological 
characteristics of AdvCOX10 mutant mice. A) Shows that the threshold for paw 
withdrawal responses to mechanical stimulation with von Frey filaments was 
significantly reduced in mutants compared to control mice. Values are means ± SEM, 
n = 17 for control and 13 for mutant, ***p<0.001 by t-test. B) Shows that the latency 
for paw withdrawal responses from a noxious heat stimulus (Hargreaves’ test) was 
significantly reduced in mutant mice. Values are means ± SEM, n = 5 in each case, 
**p<0.01 by t-test. C) Shows in vivo noxious cold avoidance behaviour in terms of 
standing duration on a 4oC cold plate (before escaping to an insulated, room 
temperature platform) was significantly reduced in mutant mice. Values are means ± 
SEM, n = 6 for control and 7 for mutant, *p<0.05 by t-test. D) Shows that there were 
no significant differences between control mice and AdvCOX10 mutants for weight, 
Rotarod running duration or grip strength. Values are means ± SEM, n in 
parentheses; t-test p values were 0.57, 0.34 and 0.47, respectively.   
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Fig. 3 GluK1 is widely expressed in DRG nociceptive afferents and at their central 
terminals in dorsal spinal cord. A) Shows example images of dual label 
immunofluorescence identification of DRG cells expressing GluK1, peripherin (a 
marker of small nociceptive C-fibre afferents), and their co-localisation in control and 
AdvCOX10 mutant mice. Scale bar = 50 µm. B) Shows quantification of results from 
experiments outlined in A). A substantial proportion of nociceptors labelled by 
peripherin, by TRPV1 (to preferentially label the peptidergic sub-class), and by IB4 
(to preferentially label the non-peptidergic subclass) were each shown to co-express 
GluK1. No significant changes in co-expression between control and AdvCOX10 
mutant mice were identified.  C) Shows concentration-dependent Ca2+ fluorescence 
responses of dorsal spinal cord synaptoneurosomes from control mice to the 
selective GluK1 agonist, 5-iodowillardiine (5-IW) and their attenuation in the 
presence of the selective GluK1 antagonist, ACET. Values are means ± SEM, n = 4 
in each case. The EC50 for 5-IW was significantly (5.3-fold) increased in the presence 
of 100 nM ACET, from a mean of 242 nM to a mean of 1.29 µM (p<0.0001, Extra 
Sum of Squares F-test). D) Shows that Ca2+ fluorescence responses of 
synaptoneurosomes to a near-maximal 5-IW stimulus (2 µM) were significantly 
greater in mutant compared to control animals, consistent with the central 
sensitisation known to occur in chronic pain states (*p<0.05). 5-IW responses were 
significantly lower in ventral than dorsal spinal cord in both control († p<0.05, n = 6) 
and mutant mice (††† p<0.001, n = 6). Statistical analyses were by One-Way 
ANOVA with Tukey’s test.  
 
Fig. 4 Hypersensitivity of dorsal spinal cord synaptoneurosomes to GluK1 agonist in 
AdvCOX10 mutant mice is associated with P2Y1 activation. Ca
2+ fluorescence 
responses of dorsal spinal cord synaptoneurosomes to 2 µM 5-IW, together with 
modulatory effects of P2Y agents were compared between AdvCOX10 mutant mice 
and controls. Values are means ± SEM, n = 6-14. These included the P2Y1 
antagonist, MRS 2500 (100 nM), the P2Y12 antagonist, AZD 1283 (350 nM), the 
P2Y13 antagonist, MRS 2211 (20 µM) and the P2Y1 agonist, MRS 2365 (50 nM). 
Statistically significant differences between 5-IW responses of AdvCOX10 mutants 
and control mice were assessed by Two-Way ANOVA with Bonferroni’s test 
(*p<0.05, **p<0.01,***p<0.001). Statistically significant differences between the drug-
free 5-IW responses of AdvCOX10 mutants or controls and their responses in the 
presence of P2Y agents were assessed by One-Way ANOVA with Dunnett’s test (†† 
p<0.01). 
  
Fig. 5 Evaluation of any potential involvement of AMPK in the hypersensitivity 
observed in AdvCOX10 mutant mice. Using dorsal spinal cord synaptoneurosomes 
from control and AdvCOX10 mutant mice, neither Western blots for phospho-AMPKα 
(Thr172), the activated form, nor the effects of AMPK-modulating pharmacological 
agents on 5-IW-induced Ca2+ fluorescence responses, provided support for the idea 
that AMPK activation might contribute to hypersensitivity in the mutants. 
A) Shows typical example images from control and AdvCOX10 samples probed with 
specific antibodies for phospho-AMPKα (Thr172), and the ubiquitous housekeeping 
enzyme GAPDH, as loading control. Single bands were detected close to the 
expected running positions of 62 kDa and 36 kDa, respectively, with no discernible 
differences in phospho-AMPKα (Thr172) staining between control and AdvCOX10 
mutants. The bar chart shows that phospho-AMPKα (Thr172): GAPDH densitometric 
ratios from Image J analysis of scanned films were very similar between control and 
AdvCOX10 mutants (n = 4 in each case, not significant by t-test, p=0.89). B) Shows 
the effects of AMPK activators, and an inhibitor, on 5-IW-induced Ca2+ fluorescence 
responses of synaptoneurosomes. While 5-IW responses were greater in AdvCOX10 
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mutants, they were similarly attenuated by the AMPK activators, AICAR and 
A697662, and unaffected by the inhibitor, dorsomorphin; inconsistent with any role of 
AMPK activation in hypersensitivity. Values are shown as mean ± SEM, n in 
parentheses. The statistical significance of differences between corresponding 
control and mutant values was assessed by Two-Way ANOVA with Bonferroni’s test 
(*p<0.05, **p<0.01). Differences between drug-free controls and corresponding drug-
treated values were evaluated by One-Way ANOVA with Dunnett’s test († p<0.05, †† 
p<0.01). 
 
Fig. 6 P2Y1 is expressed in DRG nociceptive afferents and its expression is 
increased in AdvCOX10 mutants compared to control mice. A) Shows example 
images of dual label immunofluorescence identification of DRG cells expressing 
P2Y1, peripherin, and their co-localisation in control and AdvCOX10 mutant mice. 
Scale bar = 50 µm. B) Shows example images of P2Y1 co-localisation with TRPV1 
and IB4 staining in small DRG cells of AdvCOX10 mutant mice. Scale bar = 50 µm. 
C) Shows quantification of results from experiments outlined in A) and B). Substantial 
proportions of nociceptors labeled by peripherin, TRPV1 and IB4 were each shown 
to co-express P2Y1. In each case, the level of P2Y1 expression was increased in 
AdvCOX10 mutants compared to control mice (***p<0.001,***p<0.001, and *p<0.05, 
respectively, by t-test).   
 
Fig. 7 Reversal by P2Y1 antagonist of pain-associated hypersensitivity in AdvCOX10 
mutants both in vivo and in ex vivo tissue preparations. A) and B) Show time-courses 
of in vivo reflex paw withdrawal responses to von Frey (mechanical) and Hargreaves’ 
(thermal) tests, respectively, in both control animals and in COX10 mutants and the 
effects of intraperitoneal injection of the selective P2Y1 antagonist, MRS 2500 (2 
mg/kg in sterile saline). Mutants displayed hypersensitivity compared to controls (*, 
**, *** indicate p<0.05, 0.01 and 0.001, respectively, by Repeated Measures Two-
Way ANOVA with Bonferroni’s test. In mutants, but not control mice, MRS 2500 
caused marked reversal of hypersensitive paw withdrawal responses towards normal 
values. Values are means ± SEM, n = 4-5 in each case. († and †† indicate p<0.05 
and p<0.01, respectively, by Repeated Measures One-Way ANOVA with Dunnett’s 
test. No changes were seen in responses from control animals. C) Shows in vivo 
noxious cold avoidance behaviour in terms of standing duration on a 4oC cold plate 
compared to an insulated, room temperature, platform for control and AdvCOX10 
mutant mice, before and 30 min after intraperitoneal injection of 2mg/kg MRS 2500. 
** Indicates p<0.01; a significant reduction in cold plate standing duration for mutant 
compared to control mice and † indicates p<0.05; a significant reversal of this 
hypersensitivity due to MRS 2500, by One-Way ANOVA with Tukey’s test. Values 
are means ± SEM, n = 4 in each case. D) Shows Ca2+ fluorescence responses to 5-
IW (2 µM) of lumbar dorsal spinal cord synaptoneurosomes from control or 
AdvCOX10 mutant mice that had been treated in vivo with MRS 2500 (2 mg/kg ip, 45 
min before tissue collection). The 5-IW response was significantly increased in 
untreated mutant animal samples compared to control animals (**p<0.01), whereas 
this increment was significantly attenuated in preparations from mutant animals 
treated in vivo with MRS 2500 (†p<0.05). Values are means ± SEM, n = 12 for 
untreated controls and mutants and n = 5 for MRS 2500-treated controls and 
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